AZ Phoenix의 비소세포폐암 임상 시험
비소세포폐암 관련 연구 20개가 Phoenix 및 인근(약 30마일 이내) 지역에서 참여자를 모집하고 있습니다. 연구 항목을 열어 참여 자격 및 연구 팀 연락처를 확인하세요.
공식 연구 텍스트(영어)
연구 대상자를 모집 중이신가요? 이 페이지 상단에 노출하세요 — 30일 동안 $99 →
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
피험자 모집 중1상
- Exelixis Clinical Site #67, Phoenix
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
피험자 모집 중1/2상
- Research Site, Phoenix
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
피험자 모집 중3상
- Ironwood Cancer & Research Centers, Phoenix
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
피험자 모집 중관찰 연구
- Mayo Clinic Hospital, Phoenix
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
피험자 모집 중3상
- Mayo Clinic in Arizona - Phoenix ( Site 0147), Phoenix
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
피험자 모집 중3상
- City of Hope, Phoenix, Phoenix
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
피험자 모집 중3상
- Clinical Study Site, Phoenix
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
피험자 모집 중3상
- Banner University Medical Center Phoenix, Phoenix
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
피험자 모집 중1상
- Mayo Clinic, Phoenix
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
피험자 모집 중1/2상
- Mayo Clinic Arizona, Phoenix
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
피험자 모집 중1/2상
- Mayo Clinic Arizona, Phoenix
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
피험자 모집 중3상
- Mayo Clinic Hospital in Arizona, Phoenix
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
피험자 모집 중1/2상
- Mayo Clinic Hospital - Arizona, Phoenix
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
피험자 모집 중1/2상
- USOR HonorHealth, Phoenix
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
피험자 모집 중1상
- Mayo Clinic Hospital, Phoenix
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
피험자 모집 중1상
- Mayo Clinic Hospital, Phoenix
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
피험자 모집 중3상
- Mayo Clinic Hospital in Arizona, Phoenix
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
피험자 모집 중1상
- Mayo Clinic Comprehensive Cancer Center, Phoenix
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
피험자 모집 중관찰 연구
- Cancer Center at Saint Joseph's, Phoenix
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
피험자 모집 중관찰 연구
- Mayo Clinic in Arizona, Phoenix
다른 도시의 비소세포폐암 시험
- Houston, TX연구 145개
- New York City, NY연구 120개
- Arlington, VA연구 104개
- Nashville, TN연구 97개
- Boston, MA연구 90개
- Los Angeles, CA연구 87개
- St. Louis, MO연구 73개
- Chicago, IL연구 61개
- Baltimore, MD연구 60개
- San Antonio, TX연구 59개
- Columbus, OH연구 56개
- Washington, DC연구 55개
Phoenix의 다른 연구
- 유방암연구 25개
- 대장직장암연구 25개
- 비만연구 22개
- 전이성 암연구 20개
- 심부전연구 18개
- 전립선암연구 17개
- 암 (전체)연구 17개
- 다발성 골수종연구 16개
- 췌장암연구 16개
- 심혈관 질환연구 16개
- 알츠하이머병연구 15개
- 과체중연구 15개
ClinicalTrials.gov 출처, 2026. 10. 5. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.